The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | AGEO-NEO-MSI: neoadjuvant immunotherapy in dMMR/MSI colorectal cancer
Annalice Gandini, MD, Université Paris Cité, Paris, France, touches on findings from the AGEO-NEO-MSI study, a real-world international cohort evaluating neoadjuvant immune checkpoint inhibitors in mismatch repair-deficient/microsatellite instability-high colorectal cancer. High complete response rates and favorable survival outcomes were observed, with clinical complete response strongly predictive of pathological response. Treatment strategy influenced outcomes, as a short doublet immunotherapy approach showed higher response rates than prolonged single-agent therapy, while immune-related adverse events were more common with doublet regimens and appeared linked to response with single-agent treatment. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
